Aug 03,2017

Insulet Reports Second Quarter 2017 Financial Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended June 30, 2017. Second quarter 2017 revenue increased 26% to $109.8 million, compared to revenue of $87.3 million in the second quarter of 2016.

View Analyst & Ambassador Comments
Go to original news
Aug 03,2017

BD Announces Results for 2017 Third Fiscal Quarter

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.035 billion for the third fiscal quarter ended June 30, 2017. This represents a decrease of 5.1 percent from the prior-year period and is primarily due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, third quarter revenues grew 2.4 percent.

View Analyst & Ambassador Comments
Go to original news
Aug 07,2017

MannKind and One Drop Partner to Launch the A-One Clinical Trial

MannKind Corporation and One Drop today announced the first step of their collaboration with the launch of the A-ONE study, a randomized controlled trial investigating the use of Afrezza inhaled insulin and One Drop's integrated digital diabetes care platform. In May 2017, MannKind and One Drop announced a memorandum of understanding to explore collaborations related to One Drop | Premium (i.e., One Drop | Mobile app, One Drop | Chrome meter and test strips, One Drop | Experts coaching service) and Afrezza, MannKind's inhaled rapid-acting mealtime insulin. 

PRODUCT

#mobile app

#bgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 07,2017

Brighter strengthens funding for autumn product launch

Based on the authorization of the Board, the Board has decided to issue a private placement of a total of SEK 6,400,000 and 1,600,000 shares, of which SEK 3,816,000 and 954,000 shares through settlement and 2,584,000 and 646,000 shares in cash, which strengthens the company's equity.

FUNDING POST IPO-EQUITY
View Analyst & Ambassador Comments
Go to original news
Aug 08,2017

Tandem Diabetes Care Announces Issuance of Patent Related to Important Safety Features for Portable Infusion Pumps that Utilize Touchscreen Control

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.S. Patent No. 9,715,327 titled "Preventing Inadvertent Changes in Ambulatory Medical Devices". The patent relates to important safety features for the prevention of inadvertent changes in touchscreen enabled ambulatory infusion pumps, including insulin pumps. The touchscreen may be on the pump itself or be in wireless communication with a pump.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 09,2017

Senseonics Holdings, Inc. Reports Second Quarter 2017 Financial Results

Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the second quarter ended June 30, 2017. Revenue was $0.8 million for the second quarter of 2017, compared to $19,000 for the second quarter of 2016. Sequentially, revenue increased $0.3 million in the second quarter of 2017 compared to the first quarter of 2017.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2017

Nemaura Medical Inc. Reports First Quarter 2017 Financial Results

Nemaura Medical Inc. (OTC: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system, yesterday reported financial results for the first quarter ended June 30, 2017.

View Analyst & Ambassador Comments
Go to original news
Aug 10,2017

Insulet Corporation Appoints Michael R. Minogue and James C. Mullen to Board of Directors

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced the appointments of Michael R. Minogue and James C. Mullen to the Company's Board of Directors. Insulet also announced that Regina Sommer and Joseph Zakrzewski have retired from the Company's Board of Directors.

View Analyst & Ambassador Comments
Go to original news
Aug 11,2017

DarioHealth to Host Second Quarter Conference Call on August 14, 2017

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its second quarter 2017 results on Monday, August 14 and host a conference call at 9:00am ET. The Company will discuss its second quarter 2017 operating and financial results and its strategy and outlook for the remainder of 2017.

View Analyst & Ambassador Comments
Go to original news
Aug 14,2017

DarioHealth Reports Second Quarter 2017 Results

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the three-month period ended June 30, 2017. Some second Quarter Highlights - record revenues of $1,210,000, increased 81% compared to the second quarter of 2016, sequential quarterly revenue growth of 20% over the first quarter of 2017, 75% of quarterly revenues derived from test strips and other consumables, more Than 8,000 Dario™ Blood Glucose Monitoring System devices sold in the U.S.; reaching cumulative sales of more than 33,000 devices in the U.S.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES